

Theme	Session Title	Presentation No.	Abstract No.	Lecture title	Speaker	Country	
Field-oriented sessions	Immunotherapy	IMM-IS-01	IS-15	Advances in cellular immunotherapy targeting pediatric brain tumors	Duane Mitchell	USA	
		IMM-IS-02	IS-16	Today's immunotherapy for pediatric CNS tumors: briefly defining the Gordian Knot	Eugene Hwang	USA	
		IMM-IS-03	SPKR-12	Nivolumab monotherapy and nivolumab in combination with ipilimumab in pediatric patients with high-grade primary central nervous system malignancies: safety and pharmacokinetic results from CheckMate 908	Ira Dunkel	USA	
		IMM-QA-04	-	Panel discussion/Q&A	Panel discussion/Q&A		
		IMM-O-05	IMMU-31	PNOC007: H3.3K27M Specific peptide vaccine combined with poly-ICLC for the treatment of newly diagnosed HLA-A2+ H3.3K27M Diffuse Midline Gliomas (DMG)	Sabine Mueller	USA	
		IMM-O-06	IMMU-13	Dual IGF1R/IR inhibitor in combination with GD2-CAR T-cells as a potent therapeutic strategy for H3K27M-mutant diffuse midline gliomas	Emmanuel de Billy	Italy	
		IMM-O-07	IMMU-18	Favorable outcome in replication repair deficient hypermutant brain tumors to immune checkpoint inhibition: An international RRD consortium registry study	Sumedha Sudhama	Canada	
		IMM-P-08	IMMU-08	reMATCH protocol: Phase II study of ex-vivo expanded autologous tumor specific lymphocyte transfer (x-ALT) + total tumor RNA DC vaccine (tt-RNA DC) during recovery from myeloablative chemotherapy (MAC) and peripheral blood stem cell (PBSC) rescue or non-myeloablative chemotherapy (NMAC) and PBSC in patients (pts) with recurrent PNET (r-PNET)	Sridharan Gururangan	USA	
		IMM-P-09	IMMU-06	T-cell immunotherapy for pediatric brain tumors: diversity in cell surface antigen and HLA expression necessitates a multi-pronged approach	Haley Houke	USA	
		IMM-P-10	IMMU-10	Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination with partial Treg depletion in children, adolescents, and adults with relapsed high-grade gliomas	Matthias Eyrich	Germany	
		IMM-P-11	IMMU-22	Phase Ib Immunotherapy clinical trial with the use of autologous dendritic cells pulsed with an allogenic tumoral cell lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)	Andres Morales La Madrid	Spain	
		IMM-P-12	IMMU-23	A novel mass cytometry-based multi-parameter characterization of neoantigen-reactive CD8+ T-cells in patients participating in PNOC007 H3.3K27M peptide vaccine clinical trial	Takahide Nejo	USA	
		IMM-P-13	IMMU-12	Phase I/II trial of immunotherapy with fusions of dendritic cells and tumor cells for relapsed or refractory brain tumors in children and young adults	Masayoshi Yamaoka	Japan	
		IMM-P-14	IMMU-03	Updates on BrainChild-01, -02, and -03: phase 1 locoregional CAR T cell trials targeting HER2, EGFR, and B7-H3 for children with recurrent CNS tumors and DIPG	Nicholas Vitanza	USA	
		IMM-P-15	IMMU-05	B7-H3-specific CAR T cells have potent anti-tumor activity in the GL261 immune-competent murine brain tumor model	Dalia Haydar	USA	
		IMM-P-17	IMMU-15	Proteogenomic discovery of novel tumor peptides as neoantigens for personalized T cell immunotherapy in medulloblastoma	Brian Rood	USA	
		IMM-P-18	IMMU-30	Upregulated T cell and interferon-γ-related gene expression is associated with increased survival in recurrent pediatric high-grade glioma	Tom Davidson	USA	
		IMM-P-19	IMMU-02	Chimeric antigen receptor (CAR) T cell neurotoxicity correlates with pretreatment and acute CSF neurofilament light chain (NFL) levels	Juliane Gust	USA	
		IMM-P-20	IMMU-16	Intra-tumoural IL-12 delivery enables CAR T-cell immunotherapy for high-grade glioma	Karin Straathof	UK	
		IMM-P-21	IMMU-17	CAR T cells targeting the integrin alphavbeta3 exhibit robust anti-tumor responses against diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM)	Dustin Cobb	USA	
		IMM-P-22	IMMU-11	Locoregional delivery of transient GD2 CAR T cells for safe and effective treatment of DIPG	Jessica Foster	USA	
		IMM-P-23	IMMU-20	Evaluation of CAR T cells in ependymoma	Anandani Nellan	USA	
		IMM-P-24	IMMU-19	HDAC inhibitors sensitize MYC-amplified Medulloblastoma to Immunotherapy by activating the NF-κB Pathways	Siddhartha Mitra	USA	
		IMM-P-25	IMMU-21	Investigation of white blood cell characteristics in CSF samples at pediatric brain tumor diagnosis	Adam Green	USA	
		IMM-P-26	IMMU-14	Immune checkpoint inhibitor therapy for treatment of synchronous cancers in paediatric patients with constitutional mismatch repair deficiency	Jacob Henderson	USA	
		IMM-P-27	IMMU-01	Immune checkpoint inhibition for pediatric CNS tumors: A single institution experience	Chantel Cacciotti	USA	
		IMM-P-28	IMMU-27	Analysis of immune signatures in pediatric glioblastomas for patient stratification to immunotherapy	Vidya Chandramohan	USA	
		IMM-P-29	IMMU-29	AIF1 is a prognostic biomarker and correlated with immune infiltrates in gliomas	Yi Chai	China	
		IMM-P-30	IMMU-26	Disease control in a pediatric patient with newly diagnosed glioblastoma multiforme (GBM) and somatic high microsatellite instability (MSI-H) with PD-1 inhibitor Nivolumab (NIVO) only and no focal radiotherapy (RT)	Trisha Larkin	USA	
		IMM-P-31	IMMU-28	Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneity and immunosuppression in glioma	Qun Chen	China	
		IMM-P-32	IMMU-09	NIVOLUMAB therapy for a pediatric-onset primary intracranial melanoma	Utako Oba	Japan	
		IMM-P-33	IMMU-07	Immune Effector Cell Associated Neurotoxicity (ICANS) among pediatric and AYA patients:MD Anderson Cancer Center experience	Brandon Brown	USA	